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Background: Women may take hormone contraception for up to 3 decades. Patch contraceptive (PC) results in 60% higher estrogen levels 
compared to oral contraceptive (OC), yet the effects of PC vs. OC on CVD risk factors are little studied. To assess the effects of PC vs. OC 
administration on CVD risk factors, we examined indices of inflammation and oxidative stress and percent flow mediated dilation (% FMD) of the 
brachial artery.
Methods: 31 healthy women received 3 treatments for 2 months in a randomized, investigator-blinded, crossover trial: monophasic OC (each 
pill contained 35 mcg of ethinyl estradiol [EE] and 0.25 mg of norgestimate), PC or extended PC (XPC). Each patch contained 0.75 mg EE and 
6.0 mg norelgestromin. PC was 3 weeks patch and 1 week off. XPC was 7 weeks patch and 1 week off. Linear mixed models which accounts for 
repeated measures were fit to evaluate the effect of each treatment on hs-CRP, serum amyloid A (SAA), plasminogen activator inhibitor (PAI-1), total 
antioxidant capacity (TAC), and % FMD at day 21 of the 2nd month corresponding to peak hormone effect. P ≤ 0.01 was considered significant, 
accounting for multiple comparisons.
Results: Mean age was 25 +/- 7 years. Mean BMI was 22.4 +/- 2.4 kg/m2. Mean hs-CRP (mg/L) was 2.31 +/- 0.44 on OC, 3.50 +/- 0.66 on 
PC, and 3.16 +/- 0.60 on XPC. Mean TAC (mM) was 0.407 +/- 0.0005 on OC, 0.419 +/- 0.0005 on PC, and 0.427 +/- 0.0005 on XPC. Hs-CRP was 
significantly greater in PC vs. OC (p=0.001), XPC vs. OC (p=0.01), XPC vs. PC (p=0.002), and in TAC comparing XPC vs. OC (p=0.005). No significant 
differences were seen for SAA, PAI-1, or % FMD.
Conclusions: SAA and PAI-1 are unchanged indicating that inflammation is not increased with PC vs. OC. Increases in CRP and TAC likely result 
from increased hepatic protein synthesis and the intrinsic antioxidant effects, respectively, of increased estrogen levels. The net effect on vascular 
function, as measured by % FMD, is not different between treatments. These findings do not point to any significant difference in CVD risk between 
treatments.
